Literature DB >> 35128961

Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.

Jia Liu1, Kevin W Aylor1, Weidong Chai1, Eugene J Barrett1, Zhenqi Liu1.   

Abstract

Insulin increases muscle microvascular perfusion, which contributes to its metabolic action in muscle, but this action is impaired in obesity. Metformin improves endothelial function beyond its glucose lowering effects. We aim to examine whether metformin could prevent microvascular insulin resistance and endothelial dysfunction during the development of obesity. Adult male rats were fed a high-fat diet (HFD) with or without simultaneous metformin administration for either 2 or 4 wk. Insulin's metabolic and microvascular actions were determined using a combined euglycemic-hyperinsulinemic clamp and contrast-enhanced ultrasound approach. Compared with chow-fed controls, HFD feeding increased body adiposity without excess body weight gain, and this was associated with a marked decrease in insulin-mediated whole body glucose disposal and abolishment of insulin-induced muscle microvascular recruitment. Simultaneous administration of metformin fully rescued insulin-induced muscle microvascular recruitment as early as 2 wk and normalized insulin-mediated whole body glucose disposal at week 4. The divergent responses between insulin's microvascular and metabolic actions seen at week 2 were accompanied with reduced endothelial oxidative stress and vascular inflammation, and improved endothelial function and vascular insulin signaling in metformin-treated rats. In conclusions, metformin could prevent the development of microvascular insulin resistance and endothelial dysfunction by alleviating endothelial oxidative stress and vascular inflammation during obesity development.NEW & NOTEWORTHY Muscle microvascular insulin action contributes to insulin-mediated glucose use. Microvascular insulin resistance is an early event in diet-induced obesity and is associated with vascular inflammation. Metformin effectively reduces endothelial oxidative stress, improves endothelial function, and prevents microvascular insulin resistance during obesity development. These may contribute to metformin's salutary diabetes prevention and cardiovascular protective actions.

Entities:  

Keywords:  endothelial dysfunction; inflammation; metformin; microvasculature; obesity

Mesh:

Substances:

Year:  2022        PMID: 35128961      PMCID: PMC8897003          DOI: 10.1152/ajpendo.00240.2021

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  62 in total

1.  Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.

Authors:  Yoshiyuki Hattori; Kunihiro Suzuki; Sachiko Hattori; Kikuo Kasai
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

2.  Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin.

Authors:  C Bellin; D H de Wiza; N F Wiernsperger; P Rösen
Journal:  Horm Metab Res       Date:  2006-11       Impact factor: 2.936

3.  Improved endothelial function with metformin in type 2 diabetes mellitus.

Authors:  K J Mather; S Verma; T J Anderson
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

4.  Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment.

Authors:  A D Baron; M Tarshoby; G Hook; E N Lazaridis; J Cronin; A Johnson; H O Steinberg
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

5.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

6.  Metformin kinetics in healthy subjects and in patients with diabetes mellitus.

Authors:  G T Tucker; C Casey; P J Phillips; H Connor; J D Ward; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

7.  Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process.

Authors:  Dominique Detaille; Bruno Guigas; Christiane Chauvin; Cécile Batandier; Eric Fontaine; Nicolas Wiernsperger; Xavier Leverve
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

8.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

Authors:  Qingqing Ding; Weiya Xia; Jaw-Ching Liu; Jer-Yen Yang; Dung-Fang Lee; Jiahong Xia; Geoffrey Bartholomeusz; Yan Li; Yong Pan; Zheng Li; Ralf C Bargou; Jun Qin; Chien-Chen Lai; Fuu-Jen Tsai; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Mol Cell       Date:  2005-07-22       Impact factor: 17.970

9.  Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance.

Authors:  Francis Kim; Matilda Pham; Ezekiel Maloney; Norma O Rizzo; Gregory J Morton; Brent E Wisse; Elizabeth A Kirk; Alan Chait; Michael W Schwartz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-04       Impact factor: 8.311

10.  Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism.

Authors:  Weidong Chai; Zhenhua Dong; Nasui Wang; Wenhui Wang; Lijian Tao; Wenhong Cao; Zhenqi Liu
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

View more
  1 in total

1.  Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells.

Authors:  Lijing Yang; Xiaowei Jia; Dongliang Fang; Yuan Cheng; Zhaoyi Zhai; Wenyang Deng; Baopu Du; Tao Lu; Lulu Wang; Chun Yang; Yan Gao
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.